NCT03096223 is a Phase 1 clinical trial of KHK4083 in Dermatitis, Atopic, sponsored by Kyowa Kirin Co., Ltd..

Who is sponsoring NCT03096223?

NCT03096223 is sponsored by Kyowa Kirin Co., Ltd..

What drugs are being tested in NCT03096223?

Interventions in NCT03096223: KHK4083.

What condition does NCT03096223 study?

NCT03096223 studies Dermatitis, Atopic.

Is NCT03096223 still recruiting?

NCT03096223 is currently completed. Last updated 27 March 2018.

Last reviewed 2018-03-27 · How we verify

NCT03096223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis

Completed Phase 1 Last updated 27 March 2018

What this trial tests

Phase 1 trial testing KHK4083 in Dermatitis, Atopic in 26 participants. Completed in 7 February 2018.

Timeline

10 April 2017

Primary endpoint
7 February 2018

7 February 2018

Quick facts

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	10 April 2017
Primary completion	7 February 2018
Estimated completion	7 February 2018
Sites	1 location across Japan

Drugs / interventions tested

KHK4083 — full drug profile →

Conditions studied

Dermatitis, Atopic — all drugs for Dermatitis, Atopic →

Sponsor

Kyowa Kirin Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. · · 2019 · cited 100× · PMID 30825336 · DOI 10.1111/exd.13911
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.
Lé AM, Torres T. · · 2022 · cited 60× · PMID 36559247 · DOI 10.3390/pharmaceutics14122753
Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.
Litman T. · · 2019 · cited 51× · PMID 31124204 · DOI 10.1111/apm.12934
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis.
Alvarenga JM, Bieber T, Torres T. · · 2024 · cited 20× · PMID 39365406 · DOI 10.1007/s40265-024-02095-4
A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis.
Na CH, Baghoomian W, Simpson EL. · · 2020 · cited 8× · PMID 32419031 · DOI 10.2340/00015555-3515
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.
Guttman-Yassky E, Simpson E, Esfandiari E, Mano H, et al · · 2025 · cited 4× · PMID 40913705 · DOI 10.1007/s13555-025-01492-1
Atopic Dermatitis - Current State of Research on Biological Treatment.
Klasa B, Cichocka-Jarosz E. · · 2020 · cited 4× · PMID 33074181 · DOI 10.34763/jmotherandchild.2020241.2003.0000010
The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis.
Oliveira Dos Santos D, Mohamed A, Mohamed A, Alvarenga JM, et al · · 2026 · PMID 41535648 · DOI 10.1007/s40259-025-00762-w

Verify or expand the search:

Other trials of KHK4083

Trials testing the same drug.

NCT03703102 — Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis · Phase 2 · completed

Other recruiting trials for Dermatitis, Atopic

Currently open trials in the same condition.

NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting

Other Kyowa Kirin Co., Ltd. trials

Trials by the same sponsor.

NCT06926491 — Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） · Phase 3 · recruiting
NCT06812104 — Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06525636 — A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia · Phase 1, PHASE2 · recruiting
NCT06116890 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration · Phase 2 · active not recruiting
NCT06116916 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03096223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Co., Ltd.
Last refreshed: 27 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03096223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing